Thursday, May 9th 2019

08.10 – 08.15


Brief Opening of the Meeting

Paolo Ferrari, Chief Medical Officer, Ente Ospedaliero Cantonale

08.15 – 09.35

World Epidemics – Joint Session with ESC Working Group on Cardiovascular Pharmacotherapy

Chairpersons: Thomas Kahan (Stockholm, SE), Antoni Martinez-Rubio (Barcelona, ES), Hector Ventura (New Orleans, US), Luca Gabutti (Bellinzona, CH)

08.15 – 08.30
Dyslipidemia – new challenges and how to achieve targets

Heinz Drexel (Feldkirch, AT)

08.30 – 08.45
Hypertension – the many faces of systemic hypertension

Celso Amodeo (São Paulo, BR)

08.45 – 09.00
The management of patients with diabetes and heart failure: the start of a new era?

Felipe Martinez (Cordoba, AR)

09.00 – 09.15
Obesity after smoking cessation – rationale of a complex interplay

Koji Hasegawa (Kyoto, JP)

09.15 – 09.35

09.35 – 10.35

A Changing Paradigm in Management of Dyslipidemia

Chairpersons: Koji Hasegawa (Kyoto, JP), Arnold von Eckardstein (Zurich, CH), Alexandre Fredenrich (Bellinzona, CH / Nice, FR ), Heinz Drexel (Feldkirch, AT), Brenno Balestra (Mendrisio, CH)

09.35 – 09.50
The discovery of PCSK9

Catherine Boileau (Paris, FR)

09.50 – 10.05
Opportunities and barriers for the successful clinical utilisation of PCSK9

Michel Farnier (Dijon, FR)

10.05 – 10.20
PCSK9 – focus on non-hepatic locations and non LDL-cholesterol metabolism related functions

Alberico L. Catapano (Milan, IT)

10.20 – 10.35

10.35 – 11.05

Coffee Break

11.05 – 12.20

Anti-Inflammatory Treatment in Coronary Artery Disease

Chairpersons: Filippo Crea (Rome, IT), Giuseppe Vassalli (Lugano, CH), Alberto Lorenzatti (Cordoba, AR), Konstantinos Koskinas (Bern, CH)

11.05 – 11.25
The rationale for anti-inflammatory treatment

Peter Libby (Boston, US)

11.25 – 11.40
"in vivo" evidence of the inflammatory hypothesis in humans

Augusto Gallino (Bellinzona, CH)

11.40 – 11.55
The clinical evidence: targeting interleukin-1β: the CANTOS trial

Luigi M. Biasucci (Rome, IT)

11.55 – 12.10
A word of caution

Juan Carlos Kaski (London, GB)

12.10 – 12.20

12.20 – 13.20


13.20 – 14.10

Medical vs Invasive Treatment Strategies in Stable Coronary Artery Disease: Debate Session

Chairpersons: Koji Hasegawa (Kyoto, JP), Edgardo Escobar (Santiago, CL), Marco Moccetti (Lugano, CH), Claudio Ceconi (Ferrara, IT)

13.20 – 13.35
Too many patients in Europe undergo endovascular treatment for stable coronary artery disease instead of optimal medical treatment – review of recent evidence

Filippo Crea (Rome, IT)

13.35 – 13.50
Missed opportunities for successful myocardial revascularisation in stable coronary artery disease

Stefan Windecker (Bern, CH)

13.50 - 13.55 Rebuttal Filippo Crea (Rome, IT)
13.50 - 14.00 Rebuttal Stefan Windecker (Bern, CH)

14.00 – 14.10

14.10 – 15.10

Emerging Indications for New Oral Anticoagulation in Stable Coronary Artery Disease

Chairpersons: Gheorghe Dan (Bucharest, RO), Juerg H. Beer (Baden, CH), Antoni Martinez-Rubio (Barcelona, ES), Roberto Corti (Zurich, CH)

14.10 – 14.25
Rivaroxaban; from research to medicine

Elisabeth Perzborn (Wuppertal, DE)

14.25 – 14.40
NOACs in acute coronary syndrome and after coronary stent in patients with atrial fibrillation

Giovanni B. Pedrazzini (Lugano, CH)

14.40 – 15.00
Advances in anticoagulant therapies; from Aspirin to NOACs

Salim Yusuf (Hamilton, CA)

15.00 – 15.10

15.10 – 15.40

Coffee break

15.40 – 16.25

Antithrombotic Treatment in Acute Coronary Artery Disease in the World of Emerging Stents

Chairpersons: Felipe Martinez (Cordoba, AR), Doreen Tan (Singapore, SGP), Daniel Suerder (Lugano, CH), Pablo Avanzas (Oviedo, ES)

15.40 – 15.55
State of the art of antithrombotic prevention

Gilles Montalescot (Paris, FR)

15.55 – 16.10
Will emerging stents simplify antithrombotic treatment?

Marco Roffi (Geneva, CH)

16.10 – 16.25

16.25 – 17.20


Chairpersons: Heinz Drexel (Feldkirch, AT), Alvaro S. Liprandi (Buenos Aires, AR), Stefan Windecker (Bern, CH)

16.25 – 16.40
Effect of Alirocumab on cardiovascular events and all-cause mortality

Christian Mueller (Basel, CH)

16.40 – 16.55
Reduction of Lp(a) improves cardiovascular outcomes

Peter Libby (Boston, US)

16.55 – 17.10
Patients to consider for Aliricumab treatment

Alberico L. Catapano (Milan, IT)

17.10 – 17.20

17.20 – 17.50

Distinguished Eugene Braunwald Lecture

Chairpersons: Augusto Gallino (Bellinzona, CH), Juan Carlos Kaski (London, GB), Filippo Crea (Rome, IT)

17.20 – 18.40
The Inclisiran (RNAi of PCSK9) trial: an avenue for postponing CAD until the age of 100?

Eugene Braunwald (Boston, US)

17.40 – 17.50

17.50 – 18.20

Neufeld Lecture

Chairpersons: Juan Carlos Kaski (London, GB), Tiziano Moccetti (Lugano, CH), Koji Hasegawa (Kyoto, JP), Augusto Gallino (Bellinzona, CH)

The Polypill: A simple, inexpensive approach to reduce mortality and morbidity worldwide

Salim Yusuf (Hamilton, CA)